To include your compound in the COVID-19 Resource Center, submit it here.

FDA extends Eylea review

FDA extended the PDUFA date for ophthalmic candidate Eylea aflibercept from Regeneron Pharmaceuticals

Read the full 137 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE